Physician profile
Sean E Shannon
NPI 1619995487
$157,167.32
in general payments reported to CMS, 2019-2025
38 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $5,489 · 2021: $5,030 · 2022: $18K · 2023: $16K · 2024: $51K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Travel and Lodging: $18K · Food and Beverage: $11K · Education: $16.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,137.50 |
| Travel and Lodging | $17,748.26 |
| Food and Beverage | $10,502.95 |
| Education | $16.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $139,548.45 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Regeneron Healthcare Solutions, INC. | $3,566.78 | 2019-2020 | |
| Amgen INC. | $2,897.53 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Ucb, INC. | $1,417.81 | 2019-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $1,172.06 | 2021-2025 | Lupkynis |
| Genzyme Corporation | $1,060.46 | 2020-2025 | |
| Radius Health, INC. | $899.89 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $844.56 | 2019-2024 | Taltz |
| Pfizer INC. | $645.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $525.90 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $512.86 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $476.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $464.89 | 2021-2024 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.94 | 2019-2025 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $435.95 | 2019-2023 | Krystexxa |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Shannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.